Rifampin breakpoint for Acinetobacter baumannii based on pharmacokineticpharmacodynamic models with Monte Carlo simulation
Lepe, José Antonio; García-Cabrera, Emilio; Gil-Navarro, María Victoria; Aznar, Javier.
Rev. esp. quimioter
; 25(2): 134-138, jun. 2012.
Artigo em Inglês | IBECS - ES | ID: ibc-100510
Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene.
Prevalence of hypermutators among clinical Acinetobacter baumannii isolates.
In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant <i>Acinetobacter Baumannii</i>.
Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France.
Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia.
In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.
In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin.